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Abstract
Introduction This study was conducted to compare diffu-
sion tensor MR imaging (DTI) metrics of the cervical spinal
cord in asymptomatic human immunodeficiency virus
(HIV)-positive patients with those measured in healthy
volunteers, and to assess whether DTI is a valuable
diagnostic tool in the early detection of HIV-associated
myelopathy (HIVM).
Methods MR imaging of the cervical spinal cord was
performed in 20 asymptomatic HIV-positive patients and
in 20 healthy volunteers on a 3-T MR scanner. Average
fractional anisotropy (FA), mean diffusivity (MD), and
major (E1) and minor (E2, E3) eigenvalues were calculated
within regions of interest (ROIs) at the C2/3 level (central
and bilateral anterior, lateral and posterior white matter).
Results Statistical analysis showed significant differences
with regard to mean E3 values between patients and
controls (p=0.045; mixed-model analysis of variance
(ANOVA) test). Mean FA was lower, and mean MD, mean
E1, and mean E2 were higher in each measured ROI in
patients compared to controls, but these differences were
not statistically significant.
Conclusion Asymptomatic HIV-positive patients demon-
strate only subtle changes in DTI metrics measured in the
cervical spinal cord compared to healthy volunteers that
currently do not support using DTI as a diagnostic tool for
the early detection of HIVM.
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Introduction
Human immunodeficiency virus (HIV)-associated myelop-
athy (HIVM) and acquired immunodeficiency syndrome
(AIDS)-associated myelopathy are terms used for HIV-
related spinal cord abnormalities. Although HIV penetra-
tion of the central nervous system (CNS) occurs in the early
stages of HIV infection, HIVM usually manifests clinically
in advanced stages of disease, and often in conjunction with
HIV encephalopathy [1]. The histopathologic correlate in
most of these patients is vacuolar myelopathy (VM), which
has been found in up to 46.5% in autopsy studies on
patients with AIDS, but is frequently unrecognized during
life [2]. The clinical diagnosis of VM is suspected in cases
of slowly progressive lower extremity weakness, gait
disorder, and sphincter and erectile dysfunction in an
HIV-positive individual [3].
The diagnosis of HIVM remains challenging with
conventional MR imaging sequences. High signal intensity
abnormalities, without cord expansion or enhancement, as
well as spinal cord atrophy, have been described in a limited
number of cases [4, 5]. Vacuolar myelopathy is a diagnosis
of exclusion, with MR imaging currently mainly performed
to exclude infectious, degenerative, or neoplastic disorders.
Diffusion tensor MR imaging (DTI) has recently shown
promising results for the detection of early myelopathic
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DOI 10.1007/s00234-010-0782-6changes in the setting of cervical spondylotic myelopathy
(CSM) [6, 7] and in patients with spinal cord trauma [8].
There is also preliminary evidence that suggests increased
sensitivity of DTI for the detection of otherwise occult
spinal cord pathology in multiple sclerosis [9, 10].
The purpose of this study was to evaluate the ability of
DTI metrics for the detection of HIVM. The hypothesis was
that, given the early pathologic changes, DTI may be able
to detect alterations in the normal-appearing cervical spinal
cord in HIV-positive patients that precede the detectable
spinal cord changes associated with HIVM. Considering the
predilection of VM for the lateral and posterior columns of
the spinal cord, we used axial DTI for measurement of focal
regions corresponding to the known location of various
white matter tracts, and investigated whether the changes in
DTI metrics correlated with the distribution of VM.
Material and methods
Subjects
In this prospective study, 20 asymptomatic HIV-positive
patients (15 men and five women), ranging in age from 25
to 74 years (mean age, 45 years), who were referred for MR
imaging from the HIV unit between March 2007 and
February 2008, were included. Only patients without clinical
signs of myelopathy due to HIV or causes other than HIV
were selected. The CD4 cell count was measured in all
patients within 1 month of the time of MR imaging. Ten
patients had a CD4 cell count of less than 200 cells/mm
3 and
could therefore be classified as having AIDS according to
the Centers for Disease Control and Prevention [11].
Twenty healthy volunteers (nine men and 11 women)
with a mean age of 42 years (range, 25–77 years), and
without any known spinal disease or neurologic disorder,
were also recruited.
Fourpatientsandfivecontrolswithsignsofseverecervical
spondylosis on MR imaging were excluded from the study.
The study was conducted with the approval and in
accordance with the regulations of the local institutional
ethics board, and written informed consent was obtained
from all of the subjects before data acquisition.
MR imaging technique
All patients and control subjects underwent MR imaging on
a 3-T MR imaging scanner (Magnetom Tim Trio, Siemens
Medical Solutions, Erlangen, Germany). Using standard
volume neck coils, the following pulse sequences were
acquired: localizing sagittal and coronal T1-weighted
images, followed by turbo spin-echo sagittal T1-weighted
(TR/TE, 700/11 ms; matrix 256×92) and sagittal T2-
weighted (TR/TE, 3210/110 ms; matrix 256×93) images.
A 3-mm section thickness and a 220-mm field of view were
used. These sequences were performed in order to exclude
spinal cord lesions and to enable the acquisition of an axial
DTI corresponding to the level C2/C3. None of the patients
received intravenous contrast material. Axial DTI of the
upper cervical spinal cord was then performed using pulsed
gradient, spin-echo, double-shot, echo-planar imaging with
an acceleration factor of two and six non-collinear gradient
directions applied with one b value (b=1000 s/mm
2; field of
view, 180×180 mm; image matrix, 256×256; ten contigu-
ous 3-mm sections; TR/TE, 3700/98 ms). The DTI imaging
plane was parallel to the conventional axial images, and
perpendicular to the long axis of the spinal cord. The
duration of DTI acquisitions was slightly over 2 min per
patient study, during which time the patients were asked to
hold still and to try to avoid swallowing. Images were
obtained in only six directions to reduce the scan acquisition
time. Increasing the number of directions increases the scan
time, which makes the acquisition prone to physiologic
motion artifacts. For anatomic comparison, axial turbo spin-
echo T2-weighted images (TR/TE, 3484/120 ms) of the
upper cervical spine (levels C2 to C4) were obtained. In
addition, every patient underwent MR imaging of the brain
on the same MR scanner using standardized head coils and
the following sequences: axial FLAIR-weighted images,
coronal T2-weighted images, and axial T1-weighted images.
Imaging processing
The diffusion tensor images were transferred to a dedicated
workstation (Leonardo, Siemens Medical Solutions, Erlan-
gen Germany), where the data were post-processed using
the DTI module included in the Syngo® VX49B imaging
software platform. Mean diffusivity (MD) and fractional
anisotropy (FA), as well as the major (E1) and minor
eigenvalues (E2–E3), were calculated from the DTI metrics
on a voxel-by-voxel basis and displayed as two-
dimensional color and gray-scale images. From these
images, the average metric values were measured in
specific regions of interest (ROIs) according to a technique
previously described [9]. For each patient, FA, MD, and
E1–E3 were measured at the level of the C2/C3 disc space
in ROIs placed at the anterior, lateral, and posterior regions
of the spinal cord, with separate, bilateral ROIs at each of
these positions (Fig. 1). Special care was taken to avoid
cerebrospinal fluid (CSF) partial volume effects and
magnetic susceptibility and motion artifacts in the selection
of each ROI. The anterior and posterior ROIs were placed
in a paramidline location to approximate the anterior and
posterior columns. The lateral ROIs were placed to
approximate the location of the corticospinal tracts. A
seventh, slightly larger ROI was placed centrally within the
586 Neuroradiology (2011) 53:585–592cord, covering the expected location of both gray and white
matter. The ROIs were manually set on the FA images, and
then copied to the other created DTI maps. In order to be able
to accurately place the ROIs within the expected locations of
anterior,posteriorandlateralwhitematter,thesizeoftheROIs
hadtobeadaptedtotheaxialsizeofthespinalcordwhichwas
differing between various patients. Therefore, the average
areas of ROIs in the anterior, posterior, and lateral spinal cord
measured between three and seven pixels, while the centrally
located ROI measured between seven and 12 pixels.
Statistical analysis
The data for each patient and control subject consisted of
one FA, one MD, one E1, one E2, and one E3 measure
within each of seven spinal cord ROIs at the C2–C3 level
(central, right and left anterior, right and left posterior, right
and left lateral). Each measure represented the average
overall voxels within the respective region of interest. For
statistical purposes, the separate measurements from each
side were merged into one value, resulting in four ROIs
(anterior, posterior, lateral, central) for each DTI metric in
patients and controls. A mixed-model analysis of variance
(ANOVA) test was performed to determine whether any
significant differences in DTI metrics were found among
the various regions between patients and controls. For the
comparison of patients and controls for each region
separately, unpaired t-tests were used as post hoc tests.
Due to the small sample size, no corrections were
performed in order to avoid an increasing type 2 error.
All statistical calculations were performed with SPSS
software (SPSS version 16.0; SPSS, Chicago, IL), and p
Fig. 1 FA map and corresponding ADC map and B0 image showing
ROIs placed in the central, and bilateral anterior, lateral, and posterior
spinal cord at the C2–C3 level. The table on the left shows the
automatic calculation of mean value, standard deviation, size, and
minimum and maximum value of the different ROIs
Neuroradiology (2011) 53:585–592 587values of equal to or less than 0.05 were considered
statistically significant.
Results
None of the patients and healthy volunteers showed any
spinal cord abnormality on conventional MR imaging, and
there were no signs of spinal canal stenosis. In addition,
MR imaging of the brain did not show any HIV-related
abnormalities in any patient.
Mean FA was lower and mean MD was higher in each
measured ROI in patients compared with control subjects
(central, right and left anterior, right and left posterior, right
and left lateral), but did not reach statistical significance
with the mixed-model ANOVA test (p=0.315 and p=0.103,
respectively). Also, when comparing the FA and MD metrics
of different regions separately, there was no significant
difference between patients and controls (Table 1).
An analysis of variance did not show any significant
differences betweenpatients andcontrolswithregardtothe E1
and E2 values (p=0.255 and p=0.229, respectively). Howev-
er, there was a significant difference with regard to E3 values
between patients and control subjects (p=0.045; mixed-
model ANOVA test). The post hoc unpaired t-test showed
that significant differences were present only in the lateral
ROI (p=0.013). The mean E3 values in this region were
significantly higher in patients compared to control subjects
(E3=0.368 and 0.278, respectively). A line chart of the E3
values in patients and healthy volunteers is shown in Fig. 2.
Regarding the lateral ROIs in detail, there was also a
trend toward lower FA values (p=0.073) and higher MD
and E2 values in patients compared to controls (p=0.063
and p=0.083, respectively).
Comparing mean FA values of patients with CD4 cell
count below to patients with CD4 cell count above 200
cells/mm
3 the mixed-model ANOVA test did not reveal any
significant difference (p>0.05).
Discussion
DTI has been used extensively in the brain; however,
information on the clinical utility of DTI in the spinal cord
is presently limited [7, 9, 12]. This paucity of data is mainly
due to the technical challenges associated with spinal cord
DTI, such as the spinal cord’s small size, motion artifacts
related to the CSF and patient swallowing, and field
inhomogeneities, particularly at 3-T field strength and
above [13, 14]. Some of these technical difficulties have
been overcome by the development of faster imaging
sequences and by the increasing availability of 3-T MR
scanners that provide parallel imaging with improved
phased array coil technology, which alleviates some of the
artifacts associated with DTI of the spinal cord at 3 T
compared to 1.5-T MR scanners [14, 15].
A large number of studies on HIV encephalopathy have
been published in the literature, but involvement of the
spinal cord in HIV-positive patients is less well understood
and documented. The frequency of HIVM varies in
Fractional anisotropy Anterior Posterior Lateral Central
Patients 0.581±0.107 0.731±0.087 0.68±0.078 0.732±0.097
Controls 0.604±.056 0.749±0.076 0.72±0.085 0.734±0.081
P values 0.382 0.487 0.073 0.954
Mean diffusivity (x10
−3 mm
−2s
−1)
Patients 0.975±0.173 0.967±0.097 0.864±0.113 0.914±0.107
Controls 0.908±0.104 0.915±0.147 0.792±0.125 0.875±0.148
P values 0.149 0.198 0.063 0.335
E1
Patients 1.691±0.182 1.983±0.176 1.670±0.116 1.858±0.176
Controls 1.623±0.204 1.909±0.262 1.620±0.213 1.803±0.279
P values 0.275 0.301 0.355 0.456
E2
Patients 0.720±0.241 0.551±0.153 0.554±0.169 0.534±0.155
Controls 0.659±0.088 0.536±0.139 0.469±0.129 0.497±0.144
P values 0.287 0.533 0.082 0.446
E3
Patients 0.514±0.173 0.374±0.112 0.368±0.101 0.351±0.123
Controls 0.426±0.111 0.308±0.137 0.278±0.118 0.319±0.123
P values 0.063 0.100 0.013 0.429
Table 1 Average fractional an-
isotropy, mean diffusivity, and
mean E1, E2, and E3 in ROIs in
the anterior, posterior, lateral,
and central spinal cord at the
C2-C3 level, in 20 patients with
HIV and 20 healthy volunteers
(unpaired t-tests)
588 Neuroradiology (2011) 53:585–592different published clinical series, from 20 to 55% [2, 16–
19]. The predominant pathologic feature in these patients is
VM. VM is characterized by vacuolation of myelin sheaths,
and was initially described by Petito et al. in 1985 [20]i n
AIDS patients with a previously unknown progressive
myelopathy [20]. Pathologically, the disease is usually
more severe in the mid-thoracic region than in the cervical
spinal cord [20, 21]. Most published series on VM describe
a predominant involvement of the lateral and posterior
columns of the spinal cord [20, 22]; however, in a
pathologic study on 20 patients with VM, no significant
longitudinal gradient was found in score severity in the
posterior, lateral, or anterior columns [21]. Vacuoles are the
result of edematous swelling within myelin, with splitting
of the lamellae. The axons are usually normal until severe
vacuolation occurs, followed by secondary Wallerian
degeneration and axonal disruption [16, 18, 19]. The
pathogenesis of VM is unknown, but is thought to be
related to a combination of immune-mediated myelin,
oligodendrocyte injury, and simultaneous impairment of
repair mechanisms caused by a deficiency of the enzyme S-
adenosylmethionine (SAM) [23, 24]. Published reports
support an indirect relation between HIV and the patho-
genesis of vacuolar myelopathy, peripheral neuropathy, and
dementia. Because of the overlap between these syndromes,
it is not completely clear whether we are dealing with
disease entities or parts of a spectrum of tissue damage [1].
Due to the absence of randomized studies, there is no
consensus on the treatment of HIVM. However, prelimi-
nary data suggests that highly active antiretroviral therapy
(HAART) has a positive effect on the clinical course of
HIVM [25].Initial results on oral methionine supplementa-
tion for the treatment of HIVM were also promising [26];
however, according to a subsequent placebo-controlled
study, there was no clinical benefit for patients who
received methionine therapy [27]. Recently, intravenous
immunoglobulin has been successfully used in a pilot study
for the treatment of HIVM [28].
The diagnosis of VM is based on the clinical course and
the exclusion of other causes of myelopathy. MR imaging
findings of VM include bilaterally symmetrical increased
signal intensity on T2-weighted MR images, predominantly
located in the lateral and dorsal parts of the spinal cord [4,
5]. In one study, symmetrical, triangular, high-signal lesions
were found within the gracile tract over several spinal
segments, which correlated well with histopathological
findings [5]. Since the inflammatory component is missing
in VM, the blood–spinal cord barrier is not damaged, and
no enhancement is present on post-contrast images. In a
study of 21 patients with AIDS-associated myelopathy,
spinal cord atrophy was the most common MR imaging
finding (86%), followed by intrinsic cord hyperintensities
on T2-weighted imaging (29%) [29]; however, this study
lacked pathologic correlation.
Many cases of VM may have been below the limits of
resolution/detection of 1.0–1.5 T MRI units. With a high-
field unit using optimized high resolution imaging acqui-
sitions, the number and extent of intramedullary lesions
detected on neuroimaging examinations will likely more
closely approximate the actual number of cord lesions
detected by the neuropathologist.
In the present study, performed at 3-T MR using DTI in
asymptomatic HIV-positive patients, the results show that
HIV-positive patients demonstrate changes in FA and MD, as
well as the major and minor eigenvalues in the cervical spinal
cord, compared to controls in the absence of abnormalities on
conventional MR imaging. These changes consisted of
decreased mean FA and increased mean MD and E1 to E3
in all ROIs. However, the differences did not reach statistical
significance for FA, MD, E1, and E2. The only significant
increase was found in the lateral ROI of the minor eigenvalue
E3 in HIV-positive patients (p=0.013; unpaired t-test).
In the spinal cord, the minor eigenvalues typically
correspond to transverse diffusion, perpendicular to the
longitudinal axis of the spinal cord. Animal studies have
suggested that an increase in the minor eigenvalues occurs
in the setting of demyelination, increased axonal diameter,
and additional factors, including protein integrity [30]. The
increased transverse diffusion seen in the normal-appearing
spinal cord in HIV-positive patients suggests possible
microscopic demyelination and could be an early sign of
VM. The predominance of changes in DTI metrics in the
Fig. 2 Line chart of minor E3 eigenvalues in HIV-positive patients
and healthy volunteers within ROIs placed in the central, anterior,
posterior, and lateral spinal cord at the C2–C3 levels. Minor E3
eigenvalues are higher in all ROIs in HIV-positive patients compared
to healthy volunteers, with a significant difference in the lateral ROI
(p=0.013; unpaired t-test)
Neuroradiology (2011) 53:585–592 589lateral spinal cord, may reflect the distribution pattern of
VM, which has been found to be most severe in the lateral
and posterior columns [20]. Taken into account that there
was also a trend toward lower FA values (p=0.073) and
higher MD, and E2 values (p=0.063 and p=0.083,
respectively; unpaired t-test) in the lateral ROIs of HIV-
positive patients compared to controls the measurement of
lateral ROIs seems to be most promising for the early
detection of HIVM.
VM is predominantly present in immunocompromised
patients with low CD4 cell counts; however, one case of a
patient with recurrent VM and CD4 cell count of 560/ml
was recently reported [31]. In our study population, ten
patients had CD4 cell counts of less than 200/mm
3 and
therefore can be considered to have AIDS [11]; however,
the FA values of patients with and without AIDS did not
show any significant difference.
The changes in the diffusion properties of the human
spinal cord in subjects of different ages were studied and
measured in a recently published study on 42 healthy
volunteers [32]. The FA, the MD, and eigenvalues of the
cervical spinal cord were compared for ROI- and diffusion
tensor tractography (DTT)-based segmentation methods.
The results of that and similar studies suggest that,
independent of the segmentation approach used, the
diffusion characteristics are age-dependent. In our study,
patients and healthy subjects were age-matched; therefore,
any age-related bias in our results can be excluded.
No association between VM and HIV myelitis or
opportunistic infections of the CNS was found in one
neuropathological study of 74 cases of VM in AIDS
patients [33]. A close association with HIV encephalitis
was found, which occurred in 80% of severe VM, 33% of
moderate VM, and 17% of mild VM [33]. In our limited
series, no patient had clinical or radiological signs of an
HIV-related brain abnormality.
Our study has several limitations. First, the number of
patients was relatively small. It might be possible that by
inclusion of a larger study population the differences in the
lateral ROIs of all DTI metrics would become significantly
and that the measurement of the lateral columns subse-
quently could be useful as an early marker for HIVM.
Another potential limitation is one which is a challenge
when acquiring DTI data of the spinal cord. We had
experimented with various navigator sequences and also
attempted cardiac gating to overcome some of the issues
with CSF pulsation. However, when cardiac gating, the
acquisition times became prohibitively long in terms of the
data then suffering from respiratory and swallowing
artefact. As a compromise, we utilized parallel imaging to
reduce the acquisition time and reduce the gross motion.
Newer sequences and techniques will allow us to acquire
DTI data in a motion pulsatile cord as well as overcome
some of the limitations with field inhomogeneity and
Nyquist artifact. Another technical limitation is the ability
to acquire DTI data from the thoracic spinal cord. The
homogeneity and better S/N in the volume neck coil for
cervical cord DTI makes for superior data reproducibility
than the use of the conventional phased array surface spine
coil in the thoracic region. Therefore, we performed DTI of
the cervical cord instead of the thoracic spinal cord
although, according to the literature the pathology in VM
seems to start in the mid-low thoracic cord, with cervical
involvement as the disease becomes more severe [21].
Again, with improvements in sequence development and
coil technology, this will be less of a limitation.
In addition, we included only asymptomatic HIV-positive
patients, who may not have severe changes in the spinal cord.
Inanautopsy-based,case–control study,46.5% ofspinalcord
specimens showed changes consistent with VM but only
26.8% of these cases had clinical symptoms of VM [2]. The
presence of symptomatic myelopathy was related to the
pathologic severity of the changes in the spinal cord [2].
It could be argued that the comparison of symptomatic
instead of asymptomatic patients with healthy individuals
could have revealed more differences in DTI. However, we
decided against this approach for two reasons: first, patients
with clinical symptoms of HIVM frequently show abnormal-
ities already seen with conventional MR imaging, such as
spinal cord T2-hyperintensities and atrophy [29], and DTI
may not provide any additional clinically relevant informa-
tion. Our main aim was to test a new method for the detection
of subtle changes in the spinal cord that was superior to the
currently routinely performed conventional MR imaging and
therefore we decided to include asymptomatic HIV-positive
patients only that could probably benefit from DTI.
Second, the number of HIV-positive patients with
neurological disorders that can be attributed to HIVM has
obviously decreased since the introduction of HAART [34],
although controversies on the efficacy of HAART in the
treatment of HIVM exist in the literature [35–37]. It is
unknown if HAART has effectively reduced the incidence
of vacuolization of the spinal cord or just mitigated the
severity or progression of the demyelinating disease [38]. In
this context, it would be interesting to examine patients
with and without HAART to see if there is a difference, and
to compare the DTI parameters with immunological and
virological data. For further understanding of HIVM and its
imaging findings, it would also be useful to include patients
with HIVencephalopathy and to investigate the relationship
between spinal cord and brain abnormalities.
To our knowledge, our study is the first to address DTI in
HIVM,andfurtherworkregardingthe useofthistechnique in
symptomatic patients with and without abnormalities on
conventional MR imaging and with HIV encephalopathy as
well as in patients with and without HAART is required.
590 Neuroradiology (2011) 53:585–592Conclusion
DTI of the cervical spinal cord showed slightly decreased
mean FA and increased mean MD, and E1 to E3 values in
all ROIs in HIV-positive patients compared to healthy
controls, but reached statistical significance in the lateral
measurement of the minor eigenvalue E3 only. Our initial
results therefore do not support the use of DTI for early
detection of HIVM in asymptomatic HIV-positive patients;
however, the fact that the differences in DTI metrics
between patients and controls were most obvious in the
lateral column of the cervical spinal cord could serve as a
starting point for further DTI studies on HIVM.
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